Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19750314 | 0.82 | CHRM2 (0.49) | ALDH1A1LMNAANPEPL3MBTL1ABCB1 | |
| SCHEMBL9512804 | 0.82 | ALDH1A1 (0.72) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL20749891 | 0.81 | CHRM2 (0.51) | ALDH1A1LMNAUSP2ANPEPL3MBTL1 | |
| SCHEMBL14276784 | 0.81 | ALDH1A1 (0.70) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL500091 | 0.81 | ALDH1A1 (0.96) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL7979638 | 0.79 | ALDH1A1 (0.68) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL27899777 | 0.79 | ALDH1A1 (0.93) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL7979632 | 0.79 | ALDH1A1 (0.68) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL11668730 | 0.79 | ALDH1A1 (0.62) | ALDH1A1LMNAUSP2NPC1L3MBTL1 | |
| SCHEMBL1817377 | 0.78 | ALDH1A1 (0.66) | ALDH1A1LMNAUSP2ANPEPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | ALDH1A1 3496/4885LMNA 4381/4885USP2 685/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ALDH1A1 1455/4885LMNA 2463/4885USP2 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.